Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 16 12:55PM ET
47.52
Dollar change
-1.18
Percentage change
-2.43
%
IndexRUT P/E- EPS (ttm)-0.08 Insider Own0.79% Shs Outstand48.38M Perf Week-5.61%
Market Cap2.30B Forward P/E97.54 EPS next Y0.49 Insider Trans-36.12% Shs Float48.00M Perf Month7.36%
Income-3.18M PEG- EPS next Q-0.11 Inst Own108.73% Short Float9.15% Perf Quarter21.22%
Sales197.52M P/S11.64 EPS this Y214.48% Inst Trans-1.98% Short Ratio9.20 Perf Half Y50.56%
Book/sh4.72 P/B10.06 EPS next Y507.93% ROA-1.02% Short Interest4.39M Perf Year59.29%
Cash/sh2.63 P/C18.05 EPS next 5Y- ROE-1.52% 52W Range29.24 - 53.05 Perf YTD33.44%
Dividend Est.- P/FCF150.25 EPS past 5Y19.85% ROI-1.03% 52W High-10.43% Beta1.73
Dividend TTM- Quick Ratio4.21 Sales past 5Y17.25% Gross Margin68.64% 52W Low62.53% ATR (14)1.59
Dividend Ex-Date- Current Ratio4.49 EPS Y/Y TTM80.74% Oper. Margin-3.27% RSI (14)45.85 Volatility3.14% 3.11%
Employees314 Debt/Eq0.39 Sales Y/Y TTM20.17% Profit Margin-1.61% Recom1.00 Target Price53.07
Option/ShortYes / Yes LT Debt/Eq0.36 EPS Q/Q113.62% Payout- Rel Volume0.19 Prev Close48.70
Sales Surprise1.64% EPS Surprise49.68% Sales Q/Q23.35% EarningsFeb 29 BMO Avg Volume477.54K Price47.52
SMA20-3.33% SMA500.52% SMA20023.74% Trades Volume50,811 Change-2.43%
Date Action Analyst Rating Change Price Target Change
Jan-25-24Upgrade Truist Hold → Buy $39 → $51
Aug-08-23Upgrade BTIG Research Neutral → Buy $39
Nov-10-22Downgrade BTIG Research Buy → Neutral
Nov-09-22Downgrade Truist Buy → Hold
Oct-14-22Resumed Stephens Overweight $40
Jan-11-21Downgrade Oppenheimer Outperform → Perform
Dec-18-20Initiated Stephens Overweight $31
Sep-17-20Initiated Truist Buy $24
Oct-09-19Initiated H.C. Wainwright Buy $19
Feb-28-19Downgrade Needham Buy → Hold
Mar-29-24 07:01PM
Mar-28-24 01:48PM
Mar-15-24 07:00PM
Mar-01-24 09:30AM
Feb-29-24 11:37PM
09:05AM Loading…
09:05AM
08:32AM
07:55AM
Feb-27-24 08:30AM
Feb-22-24 12:00PM
Feb-18-24 03:00AM
Feb-15-24 10:00AM
08:50AM
08:30AM
Feb-05-24 08:30AM
11:01PM Loading…
Jan-30-24 11:01PM
08:50AM
Jan-25-24 09:49AM
Jan-24-24 07:01PM
Jan-19-24 08:28PM
Jan-09-24 08:47AM
07:55AM
Jan-03-24 08:30AM
Dec-17-23 03:01AM
Dec-09-23 03:05AM
Dec-02-23 05:04AM
Nov-23-23 07:04AM
Nov-16-23 05:35PM
Nov-10-23 09:52PM
Nov-09-23 03:56PM
03:30PM Loading…
Nov-08-23 03:30PM
07:55AM
Nov-07-23 08:30AM
Nov-01-23 10:01AM
Oct-25-23 08:30AM
Oct-24-23 01:22AM
Oct-23-23 05:59PM
Oct-16-23 10:23AM
Sep-28-23 08:30AM
Sep-20-23 04:30PM
Sep-06-23 08:30AM
Aug-10-23 01:48AM
Aug-02-23 09:05AM
07:55AM
Jul-23-23 11:44AM
Jul-20-23 08:30AM
Jul-10-23 09:30AM
Jun-21-23 08:00PM
May-10-23 09:05AM
07:55AM
May-02-23 09:00AM
Apr-26-23 08:00PM
08:30AM
Apr-24-23 02:06AM
Apr-17-23 03:03PM
Feb-28-23 08:30AM
Feb-23-23 09:45AM
07:55AM
Feb-09-23 08:00AM
Jan-31-23 07:19AM
Jan-11-23 10:24PM
Jan-10-23 07:55AM
Jan-04-23 08:34AM
Dec-30-22 01:42PM
05:26AM
Dec-29-22 01:46PM
01:45PM
Nov-11-22 06:09AM
Nov-10-22 09:00AM
Nov-09-22 09:05AM
07:55AM
Oct-26-22 08:30AM
Oct-10-22 11:50AM
Sep-22-22 08:30AM
Sep-06-22 08:30AM
Aug-09-22 09:55AM
Aug-04-22 04:30AM
Aug-03-22 09:05AM
07:55AM
07:30AM
Jul-21-22 04:05PM
Jul-20-22 08:30AM
Jul-08-22 08:30AM
Jun-30-22 10:50AM
May-04-22 08:30PM
09:05AM
07:55AM
Apr-20-22 08:30AM
Apr-09-22 08:07AM
Mar-15-22 08:30AM
Mar-01-22 08:30AM
Feb-24-22 06:30PM
04:45PM
09:15AM
07:55AM
Feb-17-22 03:02PM
Feb-10-22 09:00AM
Feb-02-22 04:05PM
Jan-25-22 09:38PM
Jan-04-22 08:30AM
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rubino Alan LDirectorApr 09 '24Option Exercise4.123,00012,36020,594Apr 11 04:05 PM
ZERBE ROBERT L MDDirectorMar 27 '24Option Exercise3.743,27812,26026,673Mar 29 04:05 PM
ZERBE ROBERT L MDDirectorMar 27 '24Sale51.573,278169,04623,395Mar 29 04:05 PM
Colangelo DominickPresident and CEOMar 14 '24Option Exercise3.0217,50052,850212,370Mar 15 04:07 PM
Colangelo DominickPresident and CEOMar 14 '24Sale44.0217,500770,350194,870Mar 15 04:07 PM
Colangelo DominickPresident and CEOMar 13 '24Option Exercise3.0217,50052,850212,370Mar 15 04:07 PM
Colangelo DominickPresident and CEOMar 13 '24Sale44.6717,500781,725194,870Mar 15 04:07 PM
Halpin MichaelChief Operating OfficerMar 11 '24Sale44.717,874352,047949Mar 13 04:05 PM
Flynn Sean C.SVP, General CounselMar 08 '24Sale45.338,115367,853167Mar 11 04:07 PM
SIEGAL JONATHANPrincipal Accounting OfficerMar 07 '24Sale45.001,63473,5301,400Mar 11 04:08 PM
ZERBE ROBERT L MDDirectorFeb 20 '24Option Exercise3.747222,70024,117Feb 22 04:07 PM
Hopper Jonathan MarkChief Medical OfficerFeb 20 '24Option Exercise0.007,075058,695Feb 22 04:06 PM
SIEGAL JONATHANPrincipal Accounting OfficerFeb 20 '24Option Exercise0.002,92003,900Feb 22 04:06 PM
Mara Joseph Anthony JrChief Financial OfficerFeb 20 '24Option Exercise0.007,380020,097Feb 22 04:06 PM
Colangelo DominickPresident and CEOFeb 20 '24Option Exercise0.0038,8870199,013Feb 22 04:06 PM
Flynn Sean C.SVP, General CounselFeb 20 '24Option Exercise0.007,07509,059Feb 22 04:07 PM
Halpin MichaelChief Operating OfficerFeb 20 '24Option Exercise0.0011,887010,155Feb 22 04:07 PM
ZERBE ROBERT L MDDirectorFeb 20 '24Sale50.0172236,10723,395Feb 22 04:07 PM
Colangelo DominickPresident and CEOFeb 15 '24Option Exercise3.0217,50052,850191,508Feb 16 04:05 PM
Colangelo DominickPresident and CEOFeb 15 '24Sale48.8517,500854,875174,008Feb 16 04:05 PM
Colangelo DominickPresident and CEOFeb 14 '24Option Exercise3.0217,50052,850191,508Feb 16 04:05 PM
Colangelo DominickPresident and CEOFeb 14 '24Sale46.9917,500822,325174,008Feb 16 04:05 PM
Colangelo DominickPresident and CEOFeb 12 '24Option Exercise0.007,5000177,485Feb 13 04:05 PM
Halpin MichaelChief Operating OfficerFeb 12 '24Option Exercise0.003,50004,449Feb 13 04:05 PM
Hopper Jonathan MarkChief Medical OfficerFeb 12 '24Option Exercise0.001,625054,759Feb 13 04:06 PM
ZERBE ROBERT L MDDirectorJan 29 '24Sale44.222,300101,70623,395Jan 30 04:05 PM
ZERBE ROBERT L MDDirectorJan 25 '24Sale44.022008,80425,695Jan 29 04:05 PM
ZERBE ROBERT L MDDirectorJan 22 '24Option Exercise4.123,00012,36028,895Jan 24 04:05 PM
ZERBE ROBERT L MDDirectorJan 22 '24Sale41.858,000334,77525,895Jan 24 04:05 PM
Colangelo DominickPresident and CEOJan 18 '24Option Exercise3.0216,72650,513186,711Jan 19 04:06 PM
Colangelo DominickPresident and CEOJan 18 '24Sale38.5816,726645,289169,985Jan 19 04:06 PM
Colangelo DominickPresident and CEOJan 17 '24Option Exercise3.0216,72650,513186,711Jan 19 04:06 PM
Colangelo DominickPresident and CEOJan 17 '24Sale37.9716,726635,086169,985Jan 19 04:06 PM
ZERBE ROBERT L MDDirectorJan 12 '24Sale38.092,20083,79830,895Jan 16 04:05 PM
Colangelo DominickPresident and CEODec 14 '23Option Exercise3.5712,00042,840181,985Dec 15 04:05 PM
Colangelo DominickPresident and CEODec 14 '23Sale37.1212,000445,440169,985Dec 15 04:05 PM
Wotton Paul KDirectorDec 14 '23Sale37.315,000186,55026,802Dec 15 04:07 PM
Flynn Sean C.SVP, General CounselDec 14 '23Sale37.451063,9704,467Dec 15 04:07 PM
Colangelo DominickPresident and CEODec 13 '23Option Exercise3.5712,00042,840181,985Dec 15 04:05 PM
Colangelo DominickPresident and CEODec 13 '23Sale34.0312,000408,360169,985Dec 15 04:05 PM
Flynn Sean C.SVP, General CounselDec 13 '23Sale34.201,43248,9744,573Dec 15 04:07 PM
Colangelo DominickPresident and CEODec 07 '23Option Exercise3.5712,00042,840188,742Dec 08 04:05 PM
Colangelo DominickPresident and CEODec 07 '23Sale33.8412,000406,080176,742Dec 08 04:05 PM
Colangelo DominickPresident and CEODec 06 '23Option Exercise3.5712,39744,257189,139Dec 08 04:05 PM
Colangelo DominickPresident and CEODec 06 '23Sale34.4312,397426,829176,742Dec 08 04:05 PM
Halpin MichaelChief Operating OfficerNov 30 '23Option Exercise7.2017,447125,61818,274Dec 01 04:05 PM
Halpin MichaelChief Operating OfficerNov 30 '23Sale35.4117,447617,798827Dec 01 04:05 PM
Hopper Jonathan MarkChief Medical OfficerNov 20 '23Option Exercise10.955,00054,75058,007Nov 22 04:05 PM
Hopper Jonathan MarkChief Medical OfficerNov 20 '23Sale36.405,000182,00053,007Nov 22 04:05 PM
SIEGAL JONATHANPrincipal Accounting OfficerNov 15 '23Sale37.7066224,9541,305Nov 17 04:06 PM
ZERBE ROBERT L MDDirectorNov 15 '23Sale38.0230011,40633,095Nov 17 04:06 PM
SIEGAL JONATHANPrincipal Accounting OfficerOct 02 '23Option Exercise0.0093802,134Oct 04 04:05 PM
ZERBE ROBERT L MDDirectorJul 14 '23Sale38.841,00038,84033,395Jul 17 04:05 PM
ZERBE ROBERT L MDDirectorJun 22 '23Sale36.003,000108,00034,395Jun 26 04:05 PM
Rubino Alan LDirectorApr 25 '23Option Exercise10.603,00031,80014,994Apr 27 04:03 PM